Kymera Therapeutics Q2 revenue misses expectations, net loss widens
Overview
Kymera Q2 revenue misses analyst expectations, net income also missed, per LSEG data
Co remains well-capitalized with $1 bln cash, strategic partnership with Gilead
Outlook
Company has cash runway into second half of 2028
Kymera's Gilead partnership could yield up to $750 mln
Result Drivers
GILEAD PARTNERSHIP - Strategic partnership to develop CDK2 degraders, with potential payments up to $750 mln
CASH POSITION - Well-capitalized with $1 bln cash, providing runway into the second half of 2028
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Miss | $11.48 mln | $23.40 mln (19 Analysts) |
Q2 EPS |
| -$0.95 |
|
Q2 Net Income | Miss | -$76.61 mln | -$66.80 mln (18 Analysts) |
Q2 Operating Expenses |
| $96.03 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 20 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Kymera Therapeutics Inc is $60.00, about 32.3% above its August 8 closing price of $40.62
Press Release: ID:nGNX8Xp8j3
Related Articles
Seth Klarman Portfolio
TradingKey - Seth Klarman, the Baupost value investor, long had the distinction of navigating doubt with surgeon-like precision. The technique is married to asymmetric bets, deep margin-of-safety work, and, of course, in many cases, a dash of contrarian genius..jfif)
U.S. Stock Strategy: The Rapid Development of AI Signals a Promising Future
TradingKey - Since Trump announced a 90-day suspension of the "reciprocal tariffs" imposed on certain countries on 9 April this year, all three major U.S. stock indices have recorded significant gains. Looking ahead, against the backdrop of easing global trade frictions.
China July Inflation Commentary: CPI Exceeds Expectations
TradingKey - On 9 August 2025, China's National Bureau of Statistics released inflation data for July. The Consumer Price Index (CPI) rose by 0.4% month-on-month, reversing the previous month's 0.1% decline, while remaining unchanged year-on-year. Core CPI increased by 0.8% year-on-year.
U.S. CPI Preview: Bullish Outlook for U.S. Stocks Continues
TradingKey - On 12 August 2025, the U.S. will release its July CPI data. Market consensus forecasts a year-over-year headline CPI increase of 2.8% and a core CPI rise of 3%, both up 0.1 percentage points from June. We align with these widely held market expectations. Breaking it down by category...
[IN-DEPTH ANALYSIS] LULU: Can it Recover from the Drop?
TradingKey - Thesis Among the stocks of the twenty largest clothing companies by revenue, Lululemon has the fifth lowest forward PE ratio. With all the negative sentiment revolving around the stock, we believe their multiple should be higher.
